The company selected the platform to help streamline its drug discovery data management process
SEONGNAM-SI, South Korea and BURLINGAME, California, July 29, 2020 /PRNewswire/ -- Oscotec, a Korean biotech company engaged in the clinical stage discovery of novel drug candidates for unmet needs, announced today that it has successfully deployed CDD Vault to digitize the outcomes from the company's drug discovery research programs. CDD Vault is a hosted software platform that manages chemistry and biology data whilst enabling seamless collaboration. CDD Vault is developed by Collaborative Drug Discovery, Inc., a software company headquartered in San Francisco.
Oscotec's drug discovery programs are focused around small molecules targeting novel mechanisms of action. Researchers follow a rigorous drug-target-disease validation process to progress new drug candidates into the clinical stage. Oscotec's clinical pipeline consists of targeted therapeutics in immunology and oncology. The company has optimized the discovery process for the fastest development of novel therapies with the potential to transform patient lives. CDD Vault will be used as a key component of their optimization process to store, manage and analyze chemical and biological data as well as securely share research information with partners and collaborators.
"Data is arguably the most important internal asset for an R&D company. It is imperative for us to streamline our research operations and optimize the collection, sharing, and analysis of our scientific data. With CDD Vault we make sure that the data is secure, searchable, and shareable. Moreover, CDD Vault's exceptional ease of use helps us ensure that all the important data are captured and utilized properly," said Dr. Taeyoung Yoon, CEO of Oscotec. "The team at CDD has helped us with our unique setup, enabling us to be productive in a short period of time," he added.
"Oscotec has an impressive track record in drug discovery. The company has a robust pipeline that includes the EGFR inhibitor, lazertinib, and the SYK inhibitor SKI-O-703 in all in advanced stages of clinical development. We at CDD are extremely pleased to be able to support with our software platform Oscotec's unique and complex scientific data and processes," said Dr. Barry Bunin, CEO of CDD. "We are delighted that Oscotec has selected CDD Vault as their software platform for research, and we are looking forward to support them for many years to come," he concluded.
Oscotec is a clinical stage drug discovery and development company. Our mission is to create values by translating cutting edge science into innovative medicine for clinically unmet needs. We focus on discovering small molecules with a novel mechanism of action and validating the drug-target-disease hypothesis through rigorous science into clinical proof-of-concept. We aspire to become a leading "discovery engine" that provides the critical impact in developing transformative therapies that will improve patients' lives. Oscotec's clinical pipeline consists of targeted therapeutics in immunology and oncology. For more information visit: http://www.oscotec.com
About Collaborative Drug Discovery
CDD's flagship product, 'CDD Vault®', is used to manage chemical registration, structure activity relationships (SAR) and securely scale collaborations. CDD Vault® is a hosted database solution for secure management and sharing of biological and chemical data. It lets you intuitively organize chemical structures and biological study data and collaborate with internal and/or external partners through an easy-to-use web interface. Available modules include Activity & Registration, Visualization, Inventory and ELN. For more information visit www.collaborativedrug.com
Originally published on Collaborative Drug Discovery
Mariana Vaschetto, PhD
Collaborative Drug Discovery, Inc.
SOURCE Collaborative Drug Discovery